Join
Live feed
·
PRReleasevia Quantisnow
Crinetics Pharmaceuticals Inc. logo

Crinetics Pharmaceuticals' Oral ACTH Antagonist, CRN04894, Demonstrates Pharmacologic Proof-of-Concept with Dose-Dependent Cortisol Suppression in Single Ascending Dose Portion of Phase 1 Study

ByQuantisnow·Wall Street's wire, on your screen.
CRNX· Crinetics Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CRNX (Crinetics Pharmaceuticals Inc.) and more on Quantisnow.